Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android



BLA: Biologic license application

FDA: U.S. Food and Drug Administration

NDA: New drug application


Note: The following symbols are used throughout.

! accelerated approval (final FDA approval is contingent on demonstration of a clinical benefit in a confirmatory trial)

biologic license designation

$ breakthrough therapy

# cancer drug

orphan indication

In the first half of 2019, the FDA granted 11 noteworthy NDA licenses and approved 14 noteworthy new BLAs. Part 1 of this series looked back at first-in-class and "me-too" NDA and BLA approvals, breakthrough ($) therapies, orphan indications (), cancer drugs (#), and companion diagnostics for precision cancer therapy. The remaining noteworthy FDA accomplishments are compiled in this part of the series, including dosing and other labeling changes approved for established drugs (Table P2–1), approved follow-on products, pediatric and pregnancy labeling changes, and other noteworthy FDA regulatory accomplishments related to drug efficacy and safety.

Table P2-1Marketed Drugs With Notable Labeling Changes Approved January-June, 2019

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.